All In Biotech

Drug Trial Radar · NCT02246595

Studying Complement Inhibition in Early, Newly Developing Septic Organ Dysfunction

A Phase II Randomized, Placebo-controlled, Double-blind, Dose Controlled Trial in Patients Suffering From Early, Newly Developing Abdominal or Pulmonary Derived Septic Organ Dysfunction to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and to Estimate Efficacy of the New Humanized Monoclonal i.v. Administered Antibody CaCP29

Last checked: Nov 19, 2026Latest source record: Apr 25, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

72

Actual

Start

Apr 2014

Primary completion

Dec 2015

Study completion Dec 2015

Sponsor

Lead sponsor
InflaRx GmbHIndustry
Sponsor type
Industry
First posted
Sep 23, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The trial enrolls patients with early severe sepsis or septic shock displaying at least one newly developed organ dysfunction and showing clinical evidence of pulmonary or abdominal infection. The primary goal of the trial is to assess the pharmacokinetics and pharmacodynamics of the new monoclonal antibody CaCP29 and to characterize safety and tolerability as well as evaluate parameters of efficacy.

Conditions

  • Severe Sepsis
  • Septic Shock

Interventions

  • CaCP29Biological

  • PlaceboBiological

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Plasma Concentration of CaCP29Time frame: 0h, 2h, 6h, 12h, 14h (only cohort 1), 24h, 26h (only cohort 2 and 3), 48h, 72h, 74h (only cohort 3), days 5, 8, 13, 28
  2. Assess the pharmacodynamic (PD) effects of CaCP29 on the change from baseline in plasma concentrations of C5aTime frame: 0h, 2h, 6h, 12h, 14h (only cohort 1), 24h, 26h (only cohort 2 and 3), 48h, 72h, 74h (only cohort 3), days 5, 8, 13, 28
  3. Safety variables will be summarized using descriptive statistics based on adverse event collectionTime frame: 28 days

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • Study Site

    Aachen, Germany

  • Study Site

    Augsburg, Germany

  • Study Site

    Bad Saarow, Germany

  • Study Site

    Berlin, Germany

  • Study Site

    Göttingen, Germany

  • Study Site

    Greifswald, Germany

  • Study Site

    Hamburg, Germany

  • Study Site

    Jena, Germany

  • Study Site

    Kiel, Germany

  • Study Site

    Leipzig, Germany

  • Study Site

    Oldenburg, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.